Head-to-head · WeighScore
AMP Health vs AM Rx
The verdict
AMP Health takes it — 66.1/100 to 49.6/100.
AMP Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. AMP Health offers compounded semaglutide (injectable and oral) from $199/mo and tirzepatide from $309/mo, plus a $79/mo subscription fee.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | AMP Health | AM Rx |
|---|---|---|
| WeighScore | 66.1/100 | 49.6/100 |
| Grade | C | C |
| Scorecard rank | #202 | #491 |
| Semaglutide | $199/mo (compounded) | $151/mo (quarterly plan, plus a separate fee, compounded) |
| Tirzepatide | $309/mo (compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #202 · C
Strengths
- Semaglutide in both injectable and oral formats
- Tirzepatide available
- 30-day satisfaction guarantee
- Personal nutrition plan and health coaching included
Where it loses points
- $79/mo subscription fee on top of medication ($278–$388/mo total)
- No visible LegitScript or PCAB accreditation
- No physical address disclosed
- States served not disclosed
- Brand Wegovy listed but out of stock
Graded #491 · C
Strengths
- Insurance coordination for brand-name GLP-1s — as low as $25/mo
- All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
- HSA and FSA accepted
- Video visits available with providers averaging 10+ years' experience
- Compounded semaglutide from $151/mo on the quarterly plan
Where it loses points
- Active FTC/DOJ lawsuit over deceptive billing and subscription practices
- Novo Nordisk false-advertising lawsuit (Aug 2025)
- Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
- Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.